Literature DB >> 21205461

Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients.

E Foïs1, V Le Guern, A Dupuy, M Humbert, L Mouthon, L Guillevin.   

Abstract

OBJECTIVES: To describe the frequency of patients with an elevated systolic pulmonary artery pressure (sPAP) estimated by Doppler echocardiography in a population of SLE patients followed in a tertiary reference centre.
METHODS: A search of our Internal Medicine Department database identified 93 SLE patients followed between 1995 and 2005. Their medical records were reviewed retrospectively. The PH threshold was defined as sPAP≥35mmHg. Characteristics of PH and non-PH SLE patients were compared using Fisher's, chi-square or Wilcoxon's exact test.
RESULTS: Elevated sPAP was detected in 12/93 (13%) patients. When analysing the mechanisms of PH, it was considered as secondary to specific lung involvement in 2 cases, due to severe left ventricular dysfunction in 1 patient and probably corresponding to SLE-associated PAH in the 9 remaining subjects. Univariate analyses showed that sPAP≥35mmHg was more common in Black subjects (50 vs. 20%, p=0.03), in patients with longer disease duration (14±8 vs. 9.5±8 years, p=0.049), and in patients with a history of peripheral nervous system involvement (25 vs. 4%, p=0.02), pericarditis (58 vs. 27%, p=0.04), anti-Sm (42 vs. 11%, p=0.01), and anticardiolipin antibodies (75 vs. 31% p=0.007).
CONCLUSIONS: PH is a relatively common complication of SLE patients managed in tertiary care centres. Doppler echocardiography allows non-invasive detection of elevated sPAP in this population that should then benefit from gold-standard techniques including right-heart catheterisation in order to confirm the diagnosis, as well as the cause and severity of PH.

Entities:  

Mesh:

Year:  2011        PMID: 21205461

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  8 in total

Review 1.  Pulmonary hypertension associated with antiphospholipid antibody: Call for a screening tool?

Authors:  Rukma Parthvi; Rutuja R Sikachi; Abhinav Agrawal; Ajay Adial; Abhinav Vulisha; Sameer Khanijo; Arunabh Talwar
Journal:  Intractable Rare Dis Res       Date:  2017-08

Review 2.  Prevalence of pulmonary hypertension in systemic lupus erythematosus: a meta-analysis.

Authors:  Tian-Tian Lv; Peng Wang; Shi-Yang Guan; Hong-Miao Li; Xiao-Mei Li; Bin Wang; Hai-Feng Pan
Journal:  Ir J Med Sci       Date:  2017-12-18       Impact factor: 1.568

3.  Cardiac manifestations of Han Chinese patients with systemic lupus erythematosus: a retrospective study.

Authors:  Ertao Jia; Hongling Geng; Qingping Liu; Yuya Xiao; Yanying Zhang; Jingjing Xie; Luhe Zhang; Xia Qiu; Li Zhong; Min Xiao; Jianyong Zhang
Journal:  Ir J Med Sci       Date:  2018-11-20       Impact factor: 1.568

Review 4.  Pulmonary hypertension in antiphospholipid syndrome.

Authors:  Stéphane Zuily; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

Review 5.  Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis.

Authors:  Anupama Shahane
Journal:  Rheumatol Int       Date:  2013-01-19       Impact factor: 2.631

6.  Asymptomatic pulmonary hypertension in systemic lupus erythematosus.

Authors:  Shereen R Kamel; Gihan M Omar; Ayman F Darwish; Hany T Asklany; Abdou S Ellabban
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2011-09-28

7.  Pulmonary hypertension in systemic lupus erythematosus: an independent predictor of patient survival.

Authors:  Hong Ki Min; Jae Ho Lee; Seung Min Jung; Jennifer Lee; Kwi Young Kang; Seung-Ki Kwok; Ji Hyeon Ju; Kyung-Su Park; Sung-Hwan Park
Journal:  Korean J Intern Med       Date:  2015-02-27       Impact factor: 2.884

8.  Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients.

Authors:  Can Huang; Mengtao Li; Yongtai Liu; Qian Wang; Xiaoxiao Guo; Jiuliang Zhao; Jinzhi Lai; Zhuang Tian; Yan Zhao; Xiaofeng Zeng
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.